EGFR and neoplasm: Nagathihalli et al (2015) previously described the JAK inhibitor AZD1480 combined with gemcitabine-improved drug delivery in GEM models of PDAC because of enhanced remodeling of the tumor stroma (Nagathihalli et al, 2015). More recently, Src/EGFR inhibition was found to target STAT3 and remodel the tumor stroma, enhancing delivery of gemcitabine in a GEM model of PDAC (Dosch et al, 2020).